The US Food and Drug Administration's Model-Informed Drug Development Meeting Program: From Pilot to Pathway

被引：5
|
作者：
Madabushi, Rajanikanth [1 ]
Benjamin, Jessica [1 ]
Zhu, Hao [1 ]
Zineh, Issam [1 ]
机构：
[1] US FDA, Ctr Drug Evaluat & Res, Off Clin Pharmacol, Off Translat Sci, Silver Spring, MD 20993 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2024年 / 116卷 / 02期
关键词：
D O I：
10.1002/cpt.3228
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：278 / 281
页数：4
相关论文
共 50 条
  • [41] US Food and Drug Administration's perspective on aquaculture drug residues
    Oriani, JA
    XENOBIOTICS IN FISH, 1999, : 15 - 23
  • [42] Physiologically-Based Pharmacokinetic Model-Informed Drug Development for Fenebrutinib: Understanding Complex Drug-Drug Interactions
    Chen, Yuan
    Ma, Fang
    Jones, Nicholas S.
    Yoshida, Kenta
    Chiang, Po-Chang
    Durk, Matthew R.
    Wright, Matthew R.
    Jin, Jin Yan
    Chinn, Leslie W.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (06): : 332 - 341
  • [43] Opportunities and challenges for applying model-informed drug development approaches to gene therapies
    Belov, Artur
    Schultz, Kimberly
    Forshee, Richard
    Tegenge, Million A.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (04): : 286 - 290
  • [44] Model-Informed Drug Development Framework for the Development and Dose Optimization of Targeted Radiation Therapies
    Stephens, H.
    Koirala, B.
    Watson, K.
    Trame, M.
    Manon, A.
    Apgar, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S833 - S833
  • [45] Role of Model-Informed Drug Development in Confirming Additional Clinical Benefits of Dulaglutide
    Tham, Lai-San
    Geiser, Jeanne
    Tang, Cheng Cai
    Schneck, Karen
    Cox, David
    Milicevic, Zvonko
    Bethel, Angelyn
    DIABETES, 2020, 69
  • [46] Model-Informed Drug Development for Anti-Infectives: State of the Art and Future
    Rayner, Craig R.
    Smith, Patrick F.
    Andes, David
    Andrews, Kayla
    Derendorf, Hartmut
    Friberg, Lena E.
    Hanna, Debra
    Lepak, Alex
    Mills, Edward
    Polasek, Thomas M.
    Roberts, Jason A.
    Schuck, Virna
    Shelton, Mark J.
    Wesche, David
    Rowland-Yeo, Karen
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (04) : 867 - 891
  • [47] Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan
    Sasaki, Tomohiro
    JPMA MIDD Task Force, Tomohiro
    Katsube, Takayuki
    Hayato, Seiichi
    Yamaguchi, Shingo
    Tanaka, Jun
    Yoshimatsu, Hiroki
    Nakanishi, Yushi
    Kitamura, Atsushi
    Watase, Hirotaka
    Suganami, Hideki
    Matsuoka, Nobushige
    Hasegawa, Chihiro
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2025, 52 (01)
  • [48] Model-Informed Approaches to Support Drug Development for Patients With Obesity: A Regulatory Perspective
    Pan, Xiaolei
    Wang, Li
    Liu, Jiang
    Earp, Justin C.
    Yang, Yuching
    Yu, Jingyu
    Li, Fang
    Bi, Youwei
    Bhattaram, Atul
    Zhu, Hao
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 : S65 - S77
  • [49] Model-Informed Drug Development Applications and Opportunities in mRNA-LNP Therapeutics
    Zhou, Jiawei
    Rao, Rohit
    Shapiro, Monica E.
    Tania, Nessy
    Herron, Cody
    Musante, Cynthia J.
    Hughes, Jim H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025,
  • [50] Editorial: Model-informed drug development and evidence-based translational pharmacology
    Zhao, Jinxin
    Zhu, Xiao
    Tan, Songwen
    Chen, Chuanpin
    Kaddoumi, Amal
    Guo, Xiu-Li
    Lin, Yu-Wei
    Cheung, S. Y. Amy
    FRONTIERS IN PHARMACOLOGY, 2022, 13
12345